Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7554/eLife.57877 http://scihub22266oqcxt.onion/10.7554/eLife.57877 32573433!7311167!32573433     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Elife 2020 ; 9 (ä): ä Nephropedia Template TP {{tp|p=32573433|t=2020. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization |pdf=|usr=}}{{32573433}} gab.com Text Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization JO: Elife http://www.kidney.de/pget.php?&tw=1&pmid=32573433 #FOAvip We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and soluble forms of the receptor for the virus, angiotensin converting enzyme 2. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines. Twit Text FOAVip Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization ????Elife http://www.kidney.de/pget.php?&tw=1&pmid=32573433 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32573433 #FOAvip English Wikipedia <ref>{{Cite pmid|32573433}}</ref> Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization #MMPMID32573433 Klasse PJ; Moore JP Elife 2020[Jun]; 9 (ä): ä PMID32573433show ga We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and soluble forms of the receptor for the virus, angiotensin converting enzyme 2. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines. |*Immunization, Passive[MESH] |Antibodies, Monoclonal[MESH] |Antibodies, Viral[MESH] |Betacoronavirus/immunology[MESH] |Broadly Neutralizing Antibodies/immunology[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Coronavirus Infections/*immunology/*therapy[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*immunology/*therapy[MESH] |SARS-CoV-2[MESH] |Severe acute respiratory syndrome-related coronavirus/immunology[MESH]Antibodies to SARS-CoV-2 and their potential for therapeutic passive (epmc).pdf DeepDyve Pubget Overpricing